Peyronie's Disease
Section snippets
History
Francois de la Peyronie was a French Barber Surgeon who practiced from 1693 until his death in 1747 [2]. His career was prolific; he acted as the commander of the medical corps under Louis XIV, founded the Royal Academy of Surgery in 1737, and became a famous surgeon in Paris, caring for prominent Parisians and the kings of Poland and Prussia [2]. His most famous contribution to medical history is his classic paper on induratio penis plastica [1], describing “disfiguring knobs” [1] and
Etiology and molecular mechanisms
The etiology of PD is the subject of much scientific research. Historically described etiologies included the patient's sexual history or a history of “deviant behavior” [4], [5]. Forceful penetration and penile trauma have long been thought to be causative factors [6], and although other investigators have questioned their causality [7], it is likely that they remain an important triggering or epigenetic event in the development of the disease. More contemporary thinking would consider PD as a
Epidemiology
Epidemiologic data on PD are limited and inconsistent. The first published epidemiology report on PD was by Pokley in 1928 [21] and consisted of 550 patients. The historically accepted (although likely incorrect) prevalence of 1% in the American male population was popularized by studies from Ludvik and Wasserburger [22] and Devine [23]. In 1991, Lindsay and colleagues [24] reported an overall prevalence of 0.38% based upon hospital record review, estimating that at that time there were 423,000
Evaluation of the patient who has Peyronie's disease
Thorough evaluation of the patient who has PD is essential not only to diagnose the disease correctly but also to guide treatment. No universally accepted standardized evaluation for the PD man exists, nor has a validated questionnaire been developed. A suggested guideline for initial evaluation of the patient who has PD, including history, physical examination, and imaging analysis, has been published [36] and is outlined below. Subjective and objective data gathering remains discordant among
Nonsurgical therapy for Peyronie's disease
Since the first description of PD in the literature, physicians have been searching for medical therapy options with little confirmed success. Consistent successful medical therapies continue to evade the practicing urologist, although current research into the molecular pathophysiology of PD may lead to a medical cure. Several nonsurgical options are available and may stabilize or reduce deformity and improve sexual function. The evaluation of their efficacy has been compromised by small
Surgical treatment of Peyronie's disease
Surgery remains the gold standard treatment for PD. Surgery should be performed only when the disease is stable enough to ensure long-term efficacy. In general, surgery should be considered only when disease duration is 9 months to 1 year and when the disease has remained stable for at least 6 months.
Preoperative history, physical examination, and duplex ultrasonography are essential to formulating a treatment plan. A treatment algorithm was developed at Rush University Medical Center in
References (116)
Peyronie's disease (plastic induration) cause and treatment
J Urol
(1943)Proposal: trauma as the cause of the Peyronie's lesion
J Urol
(1997)Trauma as the cause of Peyronie's disease: penile fracture as a model of trauma
J Urol
(2004)- et al.
Neutrophils express tumor necrosis factor-alpha during mouse skin wound healing
J Invest Dermatol
(1995) - et al.
An animal model of Peyronie's like condition associated with an increase of transforming growth factor β mRNA and protein expression
J Urol
(1997) - et al.
Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression
J Urol
(1997) - et al.
The plasmin system in airway remodeling
Thromb Res
(2003) Mechanisms by which fibrin and fibronectin appear in healing wounds: implications for Peyronie's disease
J Urol
(1997)- et al.
Peyronie's disease is associated with an increase of plasminogen activator inhibitor-1 in fibrotic plaque
Urology
(2005) - et al.
Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture
Urology
(2004)
Introduction to Peyronie's Disease
J Urol
Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening
J Urol
A Survey of primary-care physicians and urologists regarding Peyronie's disease
J Sex Med
Defining the clinical characteristics of Peyronie's disease in young men
J Sex Med
The natural history of Peyronie's disease
J Urol
The natural history of Peyronie's disease
J Urol
A retrospective review of 307 men with Peyronie's disease
J Urol
Is colchicine effective in Peyronie's disease? A pilot study
Urology
Treatment of Peyronie's disease with potassium para-aminobenzoate (POTABA)
J Urol
Tamoxifen versus placebo in the treatment of Peyronie's disease
J Urol
L-Arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures
Nitric Oxide
Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea
J Urol
Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of peyronie's disease—a placebo-controlled pilot study
J Sex Med
Comment on topical verpamil HCl, topical trfluoperazine, and topical magnesium sulfate for the treatment of peyronie's disease—a placebo-controlled pilot study
J Sex Med
Peyronie's disease: cortisone-hyaluronidase-hydrocortisone therapy
J Urol
Peyronie's disease: results with dermo-jet injection of dexamethasone
J Urol
The use of collagenase in the treatment of Peyronie's disease
J Urol
Collagenase vs. placebo in the treatment of Peyronie's disease: a double blind study
J Urol
Intralesional verapamil injection for the treatment of Peyronie's disease
J Urol
Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long term single-blind study
Urology
Intralesional verapamil Prevents the Progression of Peyronie's Disease
Urology
Single-blind, multicenter placebo-controlled parallel study to asses the safety and efficacy of intralesional interferon-α-2b for minimally invasive treatment for Peyronie's disease
J Urol
Iontophoresis for treatment of Peyronie's disease
J Urol
A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease
J Urol
Tunica albuginea tissue analysis after electromotive drug administration
J Urol
Verapamil vs. saline in electromotive drug administration (EDMA) for Peyronie's disease: a double blind, placebo controlled trial
J Urol
Experience with a surgical algorithm for Peyronie's disease
J Urol
Modified corporoplasty for penile curvature: long-term results and patient satisfaction
J Urol
Correction of penile curvature using the 16-dot plication technique: a review of 132 patients
J Urol
Nesbit procedure for disabling Peyronie's curvature: a median follow-up of 84 months
Urology
Straightening corporoplasty for Peyronie's disease: a review of 218 patients with median follow-up of 89 months
Eur Urol
Minimally invasive intracorporeal incision of Peyronie's plaque: initial experiences with a new technique
Urology
Factors affecting the loss of length associated with tunica albuginea plication for correction of penile curvature
J Urol
Relaxing incisions in the correction of penile deformity due to Peyronie's disease
J Urol
Venous patch graft for Peyronie's disease. Part II: outcome analysis
J Urol
Corporoplasty using tunica albuginea free grafts for penile curvature: surgical technique and long-term results
J Urol
Sur quelques obstaclesqui sópposent à l'éjaculation nautrelle de la semence
Mem Acad Royale Chir
Historical review of Peyronie's disease
Cyrurgia edita et compilata
Venice
Miscellanea: peyronie's disease (fibrous cavernositis)
Cited by (90)
Penile Modeling in Peyronie's Disease: A Systematic Review of the Literature
2022, Sexual Medicine ReviewsSurgical Planning and Strategies for Peyronie's Disease
2021, Sexual Medicine ReviewsPeyronie's Disease and the Female Sexual Partner: A Comparison of the Male and Female Experience
2020, Journal of Sexual MedicineA Review of Treatment-Related Outcomes in Female Partners of Men With Peyronie's Disease—An Opportunity for Improved Assessment
2020, Sexual Medicine ReviewsCitation Excerpt :Peyronie's disease (PD) is a connective tissue disorder of the penile tunica albuginea, causing penile deformity, shortening, pain, and sexual dysfunction.1
Evaluating the Impact of Penile Girth Discrepancy on Patient Bother in Men With Peyronie's Disease: An Observational Study
2020, Journal of Sexual MedicineNon-surgical management of Peyronie's disease: State of current knowledge
2020, Progres en Urologie
Dr. Levine is a Consultant with Pfizer, Lilly, American Medical Systems, Auxilium, Coloplast; Speaker for Pfizer, Lilly, Coloplast, Auxilium; Investigator with fsPhysioMed and Auxilium.